[PDF] Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis. | Semantic Scholar (2024)

By using targeted and untargeted (metabolomic) multivariate analysis, it is demonstrated that the chemical composition of Psilocybe differs among mycelia, grain mycelIA, and fruiting bodies.

The tryptamine concentrations in mushrooms are extremely variable, representing a problem for mushroom consumers due to the apparent risk of overdose and the varied co*cktail of tryptamines in wild mushrooms could influence the medicinal effect compared to therapy with chemically pure PSB, posing a serious problem for data interpretation.

This study reexamined 94 Psilocybe fungarium specimens by DNA barcoding, evaluated the stability of psilocybin, psilocin, and their related tryptamine alkaloids in 25 specimens across the most commonly vouchered species, and explored the metabolome of cultivated P. cubensis.

A new molecular mechanism that affects p silocybin biosynthesis is revealed, which can provide a theoretical basis for improving psilocybin synthesis and the possibility for the development of biomedicine.

The structural and functional similarities of psiloids to serotonin, an essential neurotransmitter in animals, suggest that they may enhance the fitness of fungi through interference with serotonergic processes, and potential adaptive advantages psiloid may confer to fungi are proposed.

This review summarizes relevant and current information regarding the discovery of hallucinogenic mushrooms and their contained psychoactive compounds, the events that lead to their criminalization and decriminilization, and the state of knowledge of psilocybin, psilocin, and derivatives.

Psilacetin appears to be a prodrug for psilocin that displays substantial serotonin receptor activities of its own, and these compounds were more potent than their 4-phosphoryloxy counterparts.

The potential of psilocybin in the treatment of neuropsychiatry-related conditions is explored, examining recent advances as well as current research.

This review analyzes the potential of psilocybin in the treatment of addiction, depression, and end-of-life mood disorders and discusses the difficulties involved with conducting scientific research on psychedelic compounds, adverse effects, and the therapeutic measures necessary to accompany the safe and effective administration of these psychoactive chemicals.

...

...

It appears that the distribution of Psilocybe cyanescens has been expanding in Germany, and possibly other European countries, during the last 30 years, and this mushroom typically exhibits strong blueing behaviour after bruising and also spontaneously during ageing.

Both, the fungal extracts and psilocin evoked characteristic serotoninergic effects depending on the dose administered to mice, acting as an agonist/partial agonist on the serotonergic system.

This work presents an enhanced enzymatic route of psilocybin production by adding TrpB, the tryptophan synthase of the mushroom Psilocybe cubensis, to the reaction, capitalized on its substrate flexibility and shows p silocybin formation from 4-hydroxyindole and l-serine, which are less cost-intensive substrates, compared to the previous method.

Although psilocybin-containing mushrooms are not what Nordic mushroom pickers are trying to find as food or food supplement, there is a risk, admittedly small, that these mushrooms accidentally will be collected and this may be a legal problem in some Nordic countries.

This review aims to discuss metabolism of psilocybin and psilocin, by presenting all major and minor psychoactive metabolites, with clinical and forensic relevance in diagnosis.

In a combined PsiD/PsiK/ PsiM reaction, psilocybin was synthesized enzymatically in a step-economic route from 4-hydroxy-l-tryptophan.

Analysis of four Psilocybe species identified harmane, harmine, and a range of other l‐tryptophan‐derived β‐carbolines as their natural products, which was confirmed by 1D and 2D NMR spectroscopy.

...

...